On the evening of April 22, Xizang Weixinkang Pharmaceutical announced that its wholly-owned subsidiary Inner Mongolia Baiyi Pharmaceutical Co., Ltd. recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration for the potassium magnesium aspartate injection, which has passed the consistency evaluation of quality and efficacy for generic drugs. The potassium magnesium aspartate injection is an electrolyte supplement used for hypokalemia, arrhythmias caused by digitalis poisoning, as well as for the auxiliary treatment of myocarditis sequelae, congestive heart failure, and myocardial infarction